VEGFA and cardiomyopathy: It complements the findings of the EPICCURE study which trended towards an improvement in quality of life in patients that received AZD8601, however further cases are needed to better understand the optimal dose or distribution of AZD8601. Further studies using the model may be able to effectively demonstrate differences in VEGF-A expression in different forms of cardiomyopathy.